Author

M. Matasar

h-index 47 View on Semantic Scholar

We have 3 of 406 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Sep 2026

Pembrolizumab-GVD in relapsed or refractory Hodgkin lymphoma: 5-year update of a multicenter phase 2 trial.

A phase II trial assessed the safety and efficacy of pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin (pembrolizumab-GVD) in transplant-eligible patients with relapsed/refractory (rel/rel) cHL, and demonstrated a complete response (CR) rate of 95% and progression-free survival (PFS) of 100% at 13.5 mo...

Kishan K. Patel, G. Shah, H. Schöder et al. · Blood · 0 citations

Review Sep 2026

Beyond maximum grade: long-term toxicity and survivorship in haematological malignancies.

It is concluded that access to long-term care plans is highly heterogeneous, with insufficient adaptation to the specific needs of haematological malignancy survivors treated curatively or non-curatively, and it is proposed that clinical trials should include extended follow-up, direct patient reporting, and innovative...

T. Wästerlid, B. Valcárcel, Diana Presno et al. · The Lancet Haematology · 2 citations

Open access Sep 2026

Peripheral CD8⁺ T-cell clonality and NK-cell expansion mark early response to mosunetuzumab in indolent B-cell lymphoma.

Mosunetuzumab is highly effective against many B-cell lymphomas, but longitudinal immune changes induced by intermittently dosed CD20×CD3 bispecific antibodies remain incompletely characterized. We performed immune profiling of peripheral blood samples from patients receiving fixed-duration (6 months) subcutaneous mosu...

C. Milrod, A. Chorzalska, D. Bonal et al. · Blood Advances · 0 citations